Aura Biosciences, Inc. — Q1 2024 Form 10-Q
Business context and reporting period. The filing covers the three months ended March 31, 2024. Aura is a clinical-stage biotechnology company with no approved products and no product revenue. Its lead candidate, bel-sar, is being developed for early-stage choroidal melanoma, with additional programs in choroidal metastases, ocular-surface cancers and bladder cancer.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $17.1 million | $14.4 million |
| General and administrative expense | $5.3 million | $5.0 million |
| Total operating expense and operating loss | $22.3 million | $19.4 million |
| Interest income | $2.7 million | $2.0 million |
| Net loss | $19.7 million | $17.5 million |
| Basic and diluted loss per share | $0.40 | $0.46 |
| Net cash used in operating activities | $24.5 million | $16.4 million |
At March 31, 2024, cash and cash equivalents were $26.3 million and marketable securities were $176.6 million, totaling approximately $202.9 million. Total assets were $235.0 million, total liabilities $26.2 million, and accumulated deficit $307.0 million. The company reported no long-term debt; its principal disclosed contractual obligation is operating lease payments of $29.7 million, including interest.
Changes versus the prior comparable period
- Net loss increased by $2.2 million, while operating expenses rose by $2.9 million. R&D expense increased $2.6 million, primarily reflecting clinical-trial progress and personnel growth; G&A rose $0.2 million.
- Operating cash use increased by $8.0 million. Management attributed Q1 2024 cash use to the net loss and working-capital timing, including CRO-related costs associated with the Phase 3 program.
- Loss per share narrowed to $0.40 from $0.46 despite the higher net loss, alongside an increase in weighted-average shares to 49.5 million from 37.8 million.
- Cash, cash equivalents and restricted cash declined by $14.8 million during Q1 2024. The prior-year decline was $83.1 million, largely reflecting investment purchases and sales/maturities.
Margins are not meaningful because Aura has no revenue. The filing reports no Q1 2024 ATM share sales. A March 2024 shelf registration permits offerings of up to $350 million; the associated ATM prospectus provides for up to $75 million of common-stock sales.
Outlook, commentary and key risks
- Runway and funding: Management estimates existing cash and marketable securities will fund operations into the second half of 2026, based on assumptions that may prove incorrect. The financial-statement note separately states that funds are expected to cover operating and capital needs for at least 12 months from issuance. Aura expects to need substantial additional capital to complete development and commercialization; financing could dilute shareholders or constrain operations.
- Clinical plans: The global Phase 3 CoMpass trial is evaluating bel-sar against sham in approximately 100 patients with early-stage choroidal melanoma. The FDA agreed to the study design under a Special Protocol Assessment, which does not assure approval. The company expected final Phase 2 melanoma data by year-end 2024, to initiate a Phase 2 choroidal-metastases trial in 2024 with initial data expected by year-end, and to report early bladder-cancer Phase 1 data in mid-2024.
- Early clinical evidence: The filing describes interim Phase 2 melanoma results presented in 2023: local tumor control in 8 of 10 patients and visual-acuity preservation in 9 of 10 after three treatment cycles. These are interim results from a small, open-label study, not pivotal-trial outcomes. A preliminary response in the first light-activated bladder-cancer patient is also described.
- Principal risks: Bel-sar is the company’s only product candidate; pivotal-trial results, regulatory approval, patient enrollment, safety, manufacturing scale-up and market acceptance remain uncertain. Aura relies on third parties, including a single source for certain bel-sar manufacturing inputs and services. The company warns that additional funding may be unavailable or unfavorable and that trial or manufacturing delays could increase costs.
- Other items: In May 2024, Aura received notice that Rakuten Medical had assumed two agreements previously held by LI-COR; the agreements were otherwise unchanged. Aura reported no material litigation, stated disclosure controls were effective, and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Progress, enrollment and endpoint timing for the CoMpass Phase 3 trial, and whether the trial remains consistent with the SPA design.
- Whether the anticipated 2024 melanoma, choroidal-metastases and bladder-cancer data were delivered, and how final results compare with interim findings.
- Actual quarterly cash burn, investment maturities and whether management’s second-half-2026 runway estimate remains supportable.
- Any use of the $75 million ATM or broader $350 million shelf, and the resulting financing terms and shareholder dilution.
- Manufacturing-transfer progress, supply continuity and any new costs, delays or clinical-comparability requirements.